My friend Josh Fisher alerted me to something in Buster Olney’s column over the weekend about the fallout from Melky Cabrera’s positive PED test last year:
Before Melky Cabrera was suspended this past summer, the Giants were engaged in conversations with Cabrera about a deal that would’ve paid the outfielder something in the range of $75 million of $85 million …
He added in an update yesterday that the Giants said a deal wasn’t necessarily close, but there was no denial of the discussions either.
I offer this only as a reminder to those people who like to point to Cabrera’s $16 million deal as some sort of affront and/or proof that taking PEDs pays. To the contrary, Melky’s positive PED test cost him as much as $69 million dollars. SIXTY-NINE MILLION DOLLARS. Plus the salary he lost during his suspension.
I presume we are going to have stiffer PED penalties in the near future. And that the rash of positive tests for testosterone and the like last season are significant reasons for that. But to suggest that there are not deterrents against drug use in place already is ridiculous. It’s just that some people — most notably Melky Cabrera — are too clueless to be deterred.
An interesting tidbit today from The Athletic’s Ken Rosenthal, who noted that ongoing talks between agent Scott Boras and the Padres have focused more on starting pitcher Dallas Keuchel than slugger Bryce Harper. Earlier this week, there were conflicting reports on the Padres’ level of interest in Harper — MLB Network’s Jon Heyman heard the club had not ruled out another big signing after getting Manny Machado, while Kevin Acee of the San Diego Union-Tribune talked to multiple sources who believed otherwise — but any agreement between the two is looking unlikelier by the day.
As for Keuchel, Rosenthal cautions that a potential deal is still a “longshot,” especially as the team has other, cheaper options in mind. The 31-year-old southpaw turned down a qualifying offer from the Astros last year and is likely angling for something north of the five-year, $90 million contract extension he rejected from the club in 2016. He’s coming off of another solid performance in Houston, where he went 12-11 in 34 starts with a 3.74 ERA, 2.6 BB/9, 6.7 SO/9, and 3.6 fWAR through 204 2/3 innings in 2018.
While Keuchel has failed to garner substantial interest around the league this offseason, Heyman points out that the Phillies are looking to establish themselves as frontrunners for the lefty — and they’re far less likely to have hang-ups about his asking price, too.